Get the Stockscreener App
13.68
0.29%
0.04
Eyepoint Pharmaceuticals Inc stock is traded at $13.68, with a volume of 914.89K.
It is up +0.29% in the last 24 hours and up +15.83% over the past month.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
See More
Previous Close:
$13.64
Open:
$13.63
24h Volume:
914.89K
Relative Volume:
0.76
Market Cap:
$1.13B
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-7.5165
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+18.13%
1M Performance:
+15.83%
6M Performance:
+133.05%
1Y Performance:
+63.83%
1-Day Range:
$13.43
$13.97
1-Week Range:
$11.55
$14.67
52-Week Range:
$3.91
$14.91
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Name
Eyepoint Pharmaceuticals Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
13.68 | 1.13B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News
Why Institutions Believe Infibeam Avenues Limited Is Undervalued TodayStock Watchlist Updates & Collaborate and Win Together - earlytimes.in
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain double digit ROETrade Risk Report & Detailed Earnings Play Alerts - newser.com
EyePoint receives second consecutive positive recommendation from DSMC - Ophthalmology Times
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Australia
EyePoint Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock outperform energy sector in 2025Long Setup & Real-Time Volume Spike Alerts - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock beat growth indexesExit Point & Daily Technical Forecast Reports - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock trading at attractive multiplesEarnings Risk Summary & Smart Swing Trading Alerts - newser.com
How EyePoint Pharmaceuticals Inc. (PV3B) stock responds to job market shiftsPortfolio Value Summary & Verified Swing Trading Watchlist - newser.com
Is EyePoint Pharmaceuticals Inc. stock attractive for passive investorsJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
Why ETFs are accumulating EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Biggest Moves & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for EyePoint Pharmaceuticals Inc. stockForecast Cut & Daily Technical Forecast Reports - newser.com
Will EyePoint Pharmaceuticals Inc. (PV3B) stock hit Wall Street targetsQuarterly Earnings Summary & Daily Oversold Bounce Ideas - newser.com
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Yahoo Finance
How EyePoint Pharmaceuticals Inc. stock performs in high volatility marketsGold Moves & Precise Entry and Exit Recommendations - newser.com
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Bull vs Bear & Real-Time Volume Analysis - newser.com
Eyepoint Pharmaceuticals secures positive Phase 3 wet AMD trial review - Traders Union
EyePoint Gets Positive Recommendation for Wet AMD Trials From Safety Committee - MarketScreener
EyePoint (EYPT) Receives Green Light to Proceed with Phase 3 DUR - GuruFocus
Eyepoint announces positive recommendation by data safety monitoring committee for phase 3 trials for Duravyu - MarketScreener
EyePoint Pharmaceuticals Announces Positive Phase 3 Trial Update for DURAVYU™ - TradingView
EyePoint Pharmaceuticals Reports Positive DSMC Review for DURAVYU Clinical Trials with No Protocol Changes Recommended - Quiver Quantitative
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - The Manila Times
[8-K] EyePoint Pharmaceuticals, Inc. Reports Material Event | EYPT SEC FilingForm 8-K - Stock Titan
EyePoint (Nasdaq: EYPT) gets second DSMC OK for DURAVYU wet AMD Phase 3 trials - Stock Titan
What’s next for EyePoint Pharmaceuticals Inc. stock price2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Is EyePoint Pharmaceuticals Inc. stock gaining market shareWeekly Market Outlook & Daily Profit Focused Screening - newser.com
Can EyePoint Pharmaceuticals Inc. stock deliver surprise earnings beatChart Signals & Fast Exit and Entry Trade Guides - newser.com
Eyepoint Pharmaceuticals Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):